In SCCHN, the constitutive activation of STAT3 is responsible for tumour-immune evasion, producing immunosuppressive mediators and creating an immune tolerant microenvironment [65], In light of this, EGFR-independent STAT3 activation could contribute to a reduced response to cetuximab. Here, EGFR is linked to head and neck squamous cell carcinoma.